Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test

E. Tagliabue, F. Centis, A. Mastroianni, S. Martignone, S. Menard, R. Pellegrini, M. I. Colnaghi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

By immunizing a mouse with human metastatic breast tumor cells from patient effusions and infiltrated lymph nodes, a monoclonal antibody (MLuC2), which identifies a new carcinoma-associated marker, was raised. The reactivity of this reagent was studied by immunohistochemistry on live and fixed cells from tumor cell lines and on frozen sections from surgical specimens. Besides reacting with 73% of breast carcinomas, MLuC2 also reacted with 93% of non-small cell lung carcinoma (NSCLC) and with a few normal tissues. The MLuC2-recognized molecule (CaMLuC2), whose MW was 90 KDa according to immunoblotting experiments, was found to be detectable in the serum and could therefore be of particular interest for serological diagnostic applications. Since the CaMLuC2 epitope was not polyexpressed on the bearing molecule, we produced a new generation of MAbs in order to define epitopes coexpressed with CaMLuC2 on the same 90 KDa molecule, and which are therefore suitable to develop a double-determinant immunoradiometric assay (DDIRMA) for the detection of this marker in the sera of lung carcinoma patients. Different analyses by immunohistochemistry, binding inhibition tests and DDIRMA, proved that the two new reagents developed, MLuC8 and MLuC9, recognize the same or closely related epitopes, which are however different from CaMLuC2, but which are all present on the same molecule. Preliminary immunoradiometric tests performed on sera from lung cancer and control patients showed a good specificity but a low sensitivity. In fact, only 42% of the 28 tested sera samples from NSCLC patients scored positive despite the fact that more than 90% of the NSCLC expressed the relevant antigen.

Original languageEnglish
Pages (from-to)109-117
Number of pages9
JournalInternational Journal of Biological Markers
Volume5
Issue number3
Publication statusPublished - 1990

Fingerprint

Serologic Tests
Monoclonal Antibodies
Non-Small Cell Lung Carcinoma
Carcinoma
Immunoradiometric Assay
Epitopes
Molecules
Cells
Tumors
Assays
Bearings (structural)
Serum
Immunohistochemistry
Breast Neoplasms
Frozen Sections
Tumor Cell Line
Immunoblotting
Lung Neoplasms
Biomarkers
Lymph Nodes

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Tagliabue, E., Centis, F., Mastroianni, A., Martignone, S., Menard, S., Pellegrini, R., & Colnaghi, M. I. (1990). Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test. International Journal of Biological Markers, 5(3), 109-117.

Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test. / Tagliabue, E.; Centis, F.; Mastroianni, A.; Martignone, S.; Menard, S.; Pellegrini, R.; Colnaghi, M. I.

In: International Journal of Biological Markers, Vol. 5, No. 3, 1990, p. 109-117.

Research output: Contribution to journalArticle

Tagliabue, E, Centis, F, Mastroianni, A, Martignone, S, Menard, S, Pellegrini, R & Colnaghi, MI 1990, 'Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test', International Journal of Biological Markers, vol. 5, no. 3, pp. 109-117.
Tagliabue, E. ; Centis, F. ; Mastroianni, A. ; Martignone, S. ; Menard, S. ; Pellegrini, R. ; Colnaghi, M. I. / Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test. In: International Journal of Biological Markers. 1990 ; Vol. 5, No. 3. pp. 109-117.
@article{1c5ddbcb70c54607947b173d79435afd,
title = "Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test",
abstract = "By immunizing a mouse with human metastatic breast tumor cells from patient effusions and infiltrated lymph nodes, a monoclonal antibody (MLuC2), which identifies a new carcinoma-associated marker, was raised. The reactivity of this reagent was studied by immunohistochemistry on live and fixed cells from tumor cell lines and on frozen sections from surgical specimens. Besides reacting with 73{\%} of breast carcinomas, MLuC2 also reacted with 93{\%} of non-small cell lung carcinoma (NSCLC) and with a few normal tissues. The MLuC2-recognized molecule (CaMLuC2), whose MW was 90 KDa according to immunoblotting experiments, was found to be detectable in the serum and could therefore be of particular interest for serological diagnostic applications. Since the CaMLuC2 epitope was not polyexpressed on the bearing molecule, we produced a new generation of MAbs in order to define epitopes coexpressed with CaMLuC2 on the same 90 KDa molecule, and which are therefore suitable to develop a double-determinant immunoradiometric assay (DDIRMA) for the detection of this marker in the sera of lung carcinoma patients. Different analyses by immunohistochemistry, binding inhibition tests and DDIRMA, proved that the two new reagents developed, MLuC8 and MLuC9, recognize the same or closely related epitopes, which are however different from CaMLuC2, but which are all present on the same molecule. Preliminary immunoradiometric tests performed on sera from lung cancer and control patients showed a good specificity but a low sensitivity. In fact, only 42{\%} of the 28 tested sera samples from NSCLC patients scored positive despite the fact that more than 90{\%} of the NSCLC expressed the relevant antigen.",
author = "E. Tagliabue and F. Centis and A. Mastroianni and S. Martignone and S. Menard and R. Pellegrini and Colnaghi, {M. I.}",
year = "1990",
language = "English",
volume = "5",
pages = "109--117",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Production of monoclonal antibodies against a new carcinoma-associated marker in view of developing a serological test

AU - Tagliabue, E.

AU - Centis, F.

AU - Mastroianni, A.

AU - Martignone, S.

AU - Menard, S.

AU - Pellegrini, R.

AU - Colnaghi, M. I.

PY - 1990

Y1 - 1990

N2 - By immunizing a mouse with human metastatic breast tumor cells from patient effusions and infiltrated lymph nodes, a monoclonal antibody (MLuC2), which identifies a new carcinoma-associated marker, was raised. The reactivity of this reagent was studied by immunohistochemistry on live and fixed cells from tumor cell lines and on frozen sections from surgical specimens. Besides reacting with 73% of breast carcinomas, MLuC2 also reacted with 93% of non-small cell lung carcinoma (NSCLC) and with a few normal tissues. The MLuC2-recognized molecule (CaMLuC2), whose MW was 90 KDa according to immunoblotting experiments, was found to be detectable in the serum and could therefore be of particular interest for serological diagnostic applications. Since the CaMLuC2 epitope was not polyexpressed on the bearing molecule, we produced a new generation of MAbs in order to define epitopes coexpressed with CaMLuC2 on the same 90 KDa molecule, and which are therefore suitable to develop a double-determinant immunoradiometric assay (DDIRMA) for the detection of this marker in the sera of lung carcinoma patients. Different analyses by immunohistochemistry, binding inhibition tests and DDIRMA, proved that the two new reagents developed, MLuC8 and MLuC9, recognize the same or closely related epitopes, which are however different from CaMLuC2, but which are all present on the same molecule. Preliminary immunoradiometric tests performed on sera from lung cancer and control patients showed a good specificity but a low sensitivity. In fact, only 42% of the 28 tested sera samples from NSCLC patients scored positive despite the fact that more than 90% of the NSCLC expressed the relevant antigen.

AB - By immunizing a mouse with human metastatic breast tumor cells from patient effusions and infiltrated lymph nodes, a monoclonal antibody (MLuC2), which identifies a new carcinoma-associated marker, was raised. The reactivity of this reagent was studied by immunohistochemistry on live and fixed cells from tumor cell lines and on frozen sections from surgical specimens. Besides reacting with 73% of breast carcinomas, MLuC2 also reacted with 93% of non-small cell lung carcinoma (NSCLC) and with a few normal tissues. The MLuC2-recognized molecule (CaMLuC2), whose MW was 90 KDa according to immunoblotting experiments, was found to be detectable in the serum and could therefore be of particular interest for serological diagnostic applications. Since the CaMLuC2 epitope was not polyexpressed on the bearing molecule, we produced a new generation of MAbs in order to define epitopes coexpressed with CaMLuC2 on the same 90 KDa molecule, and which are therefore suitable to develop a double-determinant immunoradiometric assay (DDIRMA) for the detection of this marker in the sera of lung carcinoma patients. Different analyses by immunohistochemistry, binding inhibition tests and DDIRMA, proved that the two new reagents developed, MLuC8 and MLuC9, recognize the same or closely related epitopes, which are however different from CaMLuC2, but which are all present on the same molecule. Preliminary immunoradiometric tests performed on sera from lung cancer and control patients showed a good specificity but a low sensitivity. In fact, only 42% of the 28 tested sera samples from NSCLC patients scored positive despite the fact that more than 90% of the NSCLC expressed the relevant antigen.

UR - http://www.scopus.com/inward/record.url?scp=0025169231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025169231&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 109

EP - 117

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -